Literature DB >> 31361020

Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use.

Laura Ferraro1,2, Caterina La Cascia1, Diego Quattrone3,4,5, Lucia Sideli1,2, Domenica Matranga6, Veronica Capuccio7, Giada Tripoli2, Charlotte Gayer-Anderson8, Craig Morgan8, Musa B Sami5, Pak Sham9, Lieuwe de Haan10, Eva Velthorst10,11, Hannah E Jongsma12,13, James B Kirkbride13, Bart P F Rutten14, Alexander L Richards15, Laura Roldan16, Celso Arango16, Miquel Bernardo17, Julio Bobes18, Julio Sanjuan19, Jose Luis Santos20, Manuel Arrojo21, Ilaria Tarricone22, Andrea Tortelli23,24, Andrei Szöke24, Cristina Marta Del-Ben25, Jean-Paul Selten14,26, Michael Lynskey27, Peter B Jones12,28, Jim Van Os2,29, Daniele La Barbera1, Robin M Murray1,2,5, Marta Di Forti1,3,4,5.   

Abstract

Psychotic patients with a lifetime history of cannabis use generally show better cognitive functioning than other psychotic patients. Some authors suggest that cannabis-using patients may have been less cognitively impaired and less socially withdrawn in their premorbid life. Using a dataset comprising 948 patients with first-episode psychosis (FEP) and 1313 population controls across 6 countries, we examined the extent to which IQ and both early academic (Academic Factor [AF]) and social adjustment (Social Factor [SF]) are related to the lifetime frequency of cannabis use in both patients and controls. We expected a higher IQ and a better premorbid social adjustment in psychotic patients who had ever used cannabis compared to patients without any history of use. We did not expect such differences in controls. In both patients and controls, IQ was 3 points higher among occasional-users than in never-users (mean difference [Mdiff] = 2.9, 95% CI = [1.2, 4.7]). Both cases and control daily-users had lower AF compared to occasional (Mdiff = -0.3, 95% CI = [-0.5; -0.2]) and never-users (Mdiff = -0.4, 95% CI = [-0.6; -0.2]). Finally, patient occasional (Mdiff = 0.3, 95% CI = [0.1; 0.5]) and daily-users (Mdiff = 0.4, 95% CI = [0.2; 0.6]) had better SF than their never-using counterparts. This difference was not present in controls (Fgroup*frequency(2, 2205) = 4.995, P = .007). Our findings suggest that the better premorbid social functioning of FEP with a history of cannabis use may have contributed to their likelihood to begin using cannabis, exposing them to its reported risk-increasing effects for Psychotic Disorders.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  cognition; education; marijuana; preillness; schizophrenia; sociability

Mesh:

Year:  2020        PMID: 31361020      PMCID: PMC7147569          DOI: 10.1093/schbul/sbz077

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  93 in total

1.  Social environment, ethnicity and schizophrenia. A case-control study.

Authors:  Rosemarie Mallett; Julian Leff; Dinesh Bhugra; Dong Pang; Jing Hua Zhao
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2002-07       Impact factor: 4.328

2.  Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia.

Authors:  Christian C Joyal; Paul Hallé; Dominique Lapierre; Sheilagh Hodgins
Journal:  Schizophr Res       Date:  2003-10-01       Impact factor: 4.939

3.  Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study.

Authors:  Igor Grant; Raul Gonzalez; Catherine L Carey; Loki Natarajan; Tanya Wolfson
Journal:  J Int Neuropsychol Soc       Date:  2003-07       Impact factor: 2.892

4.  Trajectories of Substance Use Disorders in Youth: Identifying and Predicting Group Memberships.

Authors:  Chih-Yuan S Lee; Ken C Winters; Melanie M Wall
Journal:  J Child Adolesc Subst Abuse       Date:  2010-04-01

5.  Specific and generalized neuropsychological deficits: a comparison of patients with various first-episode psychosis presentations.

Authors:  Jolanta Zanelli; Abraham Reichenberg; Kevin Morgan; Paul Fearon; Eugenia Kravariti; Paola Dazzan; Craig Morgan; Caroline Zanelli; Arsime Demjaha; Peter B Jones; Gillian A Doody; Shitij Kapur; Robin M Murray
Journal:  Am J Psychiatry       Date:  2009-12-01       Impact factor: 18.112

6.  Cannabis use, gender and age of onset of schizophrenia: data from the ÆSOP study.

Authors:  Kim Donoghue; Gillian A Doody; Robin M Murray; Peter B Jones; Craig Morgan; Paola Dazzan; Jozella Hart; Rodolfo Mazzoncini; James H Maccabe
Journal:  Psychiatry Res       Date:  2014-01-04       Impact factor: 3.222

7.  High-potency cannabis and the risk of psychosis.

Authors:  Marta Di Forti; Craig Morgan; Paola Dazzan; Carmine Pariante; Valeria Mondelli; Tiago Reis Marques; Rowena Handley; Sonija Luzi; Manuela Russo; Alessandra Paparelli; Alexander Butt; Simona A Stilo; Ben Wiffen; John Powell; Robin M Murray
Journal:  Br J Psychiatry       Date:  2009-12       Impact factor: 9.319

8.  Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients.

Authors:  J Rabinowitz; E J Bromet; J Lavelle; G Carlson; B Kovasznay; J E Schwartz
Journal:  Psychol Med       Date:  1998-11       Impact factor: 7.723

9.  Sex differences in the risk of schizophrenia: evidence from meta-analysis.

Authors:  Andre Aleman; René S Kahn; Jean-Paul Selten
Journal:  Arch Gen Psychiatry       Date:  2003-06

10.  Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History.

Authors:  Ana González-Pinto; Itxaso González-Ortega; Susana Alberich; Sonia Ruiz de Azúa; Miguel Bernardo; Miquel Bioque; Bibiana Cabrera; Iluminada Corripio; Celso Arango; Antonio Lobo; Ana M Sánchez-Torres; Manuel J Cuesta
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

View more
  5 in total

1.  Childhood Maltreatment, Educational Attainment, and IQ: Findings From a Multicentric Case-control Study of First-episode Psychosis (EU-GEI).

Authors:  Lucia Sideli; Adriano Schimmenti; Daniele La Barbera; Caterina La Cascia; Laura Ferraro; Monica Aas; Luis Alameda; Eva Velthorst; Helen L Fisher; Vincenzo Caretti; Giulia Trotta; Giada Tripoli; Diego Quattrone; Charlotte Gayer-Anderson; Fabio Seminerio; Crocettarachele Sartorio; Giovanna Marrazzo; Antonio Lasalvia; Sarah Tosato; Ilaria Tarricone; Domenico Berardi; Giuseppe D'Andrea; Celso Arango; Manuel Arrojo; Miguel Bernardo; Julio Bobes; Julio Sanjuán; Jose Luis Santos; Paulo Rossi Menezes; Cristina Marta Del-Ben; Hannah E Jongsma; Peter B Jones; James B Kirkbride; Pierre-Michel Llorca; Andrea Tortelli; Baptiste Pignon; Lieuwe de Haan; Jean-Paul Selten; Jim Van Os; Bart P Rutten; Marta Di Forti; Craig Morgan; Robin M Murray
Journal:  Schizophr Bull       Date:  2022-05-07       Impact factor: 7.348

2.  The relationship of symptom dimensions with premorbid adjustment and cognitive characteristics at first episode psychosis: Findings from the EU-GEI study.

Authors:  Laura Ferraro; Caterina La Cascia; Daniele La Barbera; Teresa Sanchez-Gutierrez; Giada Tripoli; Fabio Seminerio; Crocettarachele Sartorio; Giovanna Marrazzo; Lucia Sideli; Celso Arango; Manuel Arrojo; Miguel Bernardo; Julio Bobes; Cristina Marta Del-Ben; Charlotte Gayer-Anderson; Hannah E Jongsma; James B Kirkbride; Antonio Lasalvia; Sarah Tosato; Pierre-Michel Llorca; Paulo Rossi Menezes; Bart P Rutten; Jose Luis Santos; Julio Sanjuán; Jean-Paul Selten; Andrei Szöke; Ilaria Tarricone; Roberto Muratori; Andrea Tortelli; Eva Velthorst; Victoria Rodriguez; Andrea Quattrone; Peter B Jones; Jim Van Os; Evangelos Vassos; Craig Morgan; Lieuwe de Haan; Ulrich Reininghaus; Alastair G Cardno; Marta Di Forti; Robin M Murray; Diego Quattrone
Journal:  Schizophr Res       Date:  2021-08-14       Impact factor: 4.939

3.  Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.

Authors:  Diego Quattrone; Laura Ferraro; Giada Tripoli; Caterina La Cascia; Harriet Quigley; Andrea Quattrone; Hannah E Jongsma; Simona Del Peschio; Giusy Gatto; Charlotte Gayer-Anderson; Peter B Jones; James B Kirkbride; Daniele La Barbera; Ilaria Tarricone; Domenico Berardi; Sarah Tosato; Antonio Lasalvia; Andrei Szöke; Celso Arango; Miquel Bernardo; Julio Bobes; Cristina Marta Del Ben; Paulo Rossi Menezes; Pierre-Michel Llorca; Jose Luis Santos; Julio Sanjuán; Andrea Tortelli; Eva Velthorst; Lieuwe de Haan; Bart P F Rutten; Michael T Lynskey; Tom P Freeman; Pak C Sham; Alastair G Cardno; Evangelos Vassos; Jim van Os; Craig Morgan; Ulrich Reininghaus; Cathryn M Lewis; Robin M Murray; Marta Di Forti
Journal:  Psychol Med       Date:  2020-03-18       Impact factor: 7.723

Review 4.  Cannabis and Cognitive Functioning: From Acute to Residual Effects, From Randomized Controlled Trials to Prospective Designs.

Authors:  Josiane Bourque; Stéphane Potvin
Journal:  Front Psychiatry       Date:  2021-06-10       Impact factor: 4.157

Review 5.  [Differential diagnostic distinction between substance-induced and primary psychoses: : Recommendations for general psychiatric and forensic practice].

Authors:  Dusan Hirjak; Andreas Meyer-Lindenberg; Geva A Brandt; Harald Dreßing
Journal:  Nervenarzt       Date:  2021-03-03       Impact factor: 1.214

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.